Form 4: Mirum CMO Sells Shares for Tax Obligations

Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, sold 1,822 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Summary

• Joanne Quan, Mirum Pharmaceuticals' Chief Medical Officer, reported transactions involving company stock.
• On January 21, 2026, 3,334 restricted stock units (RSUs) vested and converted into common stock.
• On January 22, 2026, Quan sold 1,822 shares of common stock at a price of $93.3252 per share.
• The sale was conducted to cover tax withholding obligations associated with the RSU vesting.
• Following these transactions, Quan beneficially owns 12,817 shares of common stock and 6,666 unvested restricted stock units.
• The remaining RSUs are scheduled to vest 1/3rd annually from January 21, 2025, over a three-year period.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to RSU vesting and subsequent tax-related sales, which is a common occurrence and does not inherently indicate a strong positive or negative sentiment about the company's future.

Positives

• The vesting of restricted stock units indicates continued long-term incentive alignment for a key executive.

Negatives

• An insider sale, even for tax purposes, reduces the executive's direct equity stake in the company.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Medical Officer slightly reduces insider ownership, but the reason (tax withholding) is routine. The vesting of RSUs aligns executive interests with shareholder value.

Next Steps

• Future vesting of the remaining 6,666 restricted stock units on the anniversaries of January 21, 2025.

Key Dates

Recommendation

This Form 4 details a routine insider transaction where the Chief Medical Officer acquired shares through RSU vesting and subsequently sold a portion to cover tax obligations. Such transactions are common and generally do not signal a significant change in the company's fundamentals or outlook, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Mirum Pharmaceuticals, MIRM, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Executive Compensation, Joanne Quan, Chief Medical Officer